2024 Informa Connect Rare Disease Innovation and Partnering Summit

Events
Written By Urjita Das

The 2024 Informa Connect Rare Disease Innovation and Partnering Summit is held this year between March 19th and 21st. The summit will be a space that brings together organizations focused on rare diseases and orphan drug development with patient advocates, patient support/services, market access, and technological development. The summit is an opportunity to be exposed to new information and resources, discuss important issues and their solutions, and hear from patients who are driving drug discovery in the rare disease realm. 

If you're also looking to connect with industry representatives, nonprofits, patients, and vendors, the summit will be a chance to help improve the quality of life for members of the rare disease community through education and advocacy. Held in Philadelphia, the summit will also host relevant experts and multidisciplinary stakeholders, including the FDA, Rare Revolution, Cornerstone Pharmaceuticals, and more. Key topics will be covered, including "Rapid Fire Case Studies Directly from the Thought Leaders Innovating in the Rare Disease Space" presented by Rare Genomics co-founder and Sudo BioSciences CBO Dr. Imran Barbar, and "Combatting Mental Health Challenges within Rare Disease," featuring founder and CEO of Angel Aid, Cristol Barrett O’Loughlin.

Register for the conference here: https://informaconnect.com/rare-disease-summit/pricing/

Urjita Das

Marketing Senior Manager

Urjita Das is a resident physician in Chicago, Illinois. She has been a part of Rare Genomics Institute (RG) since 2018. She is a blog writer, marketing senior manager, and social media content creator. She focuses her efforts on improving awareness, funding, and access to therapies for rare diseases. She brings her medical background to RG with intent to make medicine more digestible and consumable for the rare disease community.

Previous

AI in Healthcare: Revolutionizing Genomic Sequencing and Rare Disease Treatment
Next

The role of the physiotherapist in diagnosing pediatric neuromuscular diseases